IP Library Granted Patent US 10,174,066
Granted Patent B2
US 10,174,066 · App. 15/480,043 · Granted Jan 8, 2019

Methods and compositions for incorporating nucleotides

Inventors: Steven Gordon (Weston, MA); Jerzy Olejnik (Brookline, MA)
Assignee: QIAGEN WALTHAM, Inc.
C07H19/00C12Q1/6869C12Q1/6874G01N21/05G01N21/645G01N21/6428C12Q2535/101G01N2021/0346G01N2021/058G01N2021/6417G01N2021/6419G01N2021/6421G01N2021/6439G01N2021/6441G01N2021/6471G01N2201/062G01N2201/0627G01N2201/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,174,066
App. No.
15/480,043
Granted
Jan 8, 2019
Kind
B2
Abstract

The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Claims (4)

1. A labeled reversible terminator comprising a nucleotide analogue of dATP having a 3′-O group and a label, wherein the label is ROX and is attached to the nucleotide analogue of dATP though a cleavable linker comprising a disulfide bond, and wherein a removable chemical moiety caps the 3′-O group, wherein said labeled reversible terminator is in a mixture in solution with an unlabeled reversible terminator comprising a nucleotide analogue of dATP, wherein the concentration of the unlabeled nucleotide analogue of dATP is present in said solution at a higher concentration than the labeled nucleotide analogue of dATP.

2. The labeled reversible terminator of claim 1 , wherein said mixture further comprises labeled and unlabeled reversible terminator nucleotide analogues of dCTP and dGTP.

3. The labeled reversible terminator of claim 2 , wherein said unlabeled nucleotide analogues are present at a concentration between 1 uM and 100 uM.

4. The labeled reversible terminator of claim 3 , wherein said labeled nucleotide analogues are present at a concentration between 1 nM and 1 uM.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2023
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ISOPLEXIS CORPORATION
Reel/Frame 063235/0942 →
PATENT PURCHASE AGREEMENT Recorded Jul 30, 2021
From: QIAGEN SCIENCES, LLC
To: ISOPLEXIS CORPORATION
Reel/Frame 057043/0629 →
SECURITY AGREEMENT Recorded May 28, 2021
From: ISOPLEXIS CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 056421/0929 →
MERGER Recorded Nov 8, 2018
From: QIAGEN WALTHAM, INC.
To: QIAGEN SCIENCES, LLC
Reel/Frame 047923/0815 →
CHANGE OF NAME Recorded May 17, 2018
From: INTELLIGENT BIO-SYSTEMS, INC.
To: QIAGEN WALTHAM, INC.
Reel/Frame 047132/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: OLEJNIK, JERZY; GORDON, STEVEN
To: INTELLIGENT BIO-SYSTEMS, INC.
Reel/Frame 043286/0164 →
Continuity (6)
Continuation 15144079 · May 2, 2016
Continuation 14518114 · Oct 20, 2014
Division 13305415 · Nov 28, 2011
Continuation 12405779 · Mar 17, 2009
Provisional Application 61037845 · Mar 19, 2008
Related Publication 20170211141A1 · Jul 27, 2017
Cited By (2)
US 12,227,798 US 12,656,313